Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年半年度报告' which translates to '2024 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, financial indicators, and operational details for the first half of 2024. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, and it is not a full annual report (10-K). Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-08-29 Chinese
普莱柯关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 half-year performance explanation meeting (业绩说明会) for investors. It specifies the meeting date, time, location, format (online interaction), and participation instructions. It also mentions that the company's 2024 half-year report will be released on August 30, 2024, but this document itself is not the report or the financial data. The document is short (1395 characters) and serves as a notice for an upcoming investor presentation event rather than containing substantive financial results or analysis. According to the classification rules, such announcements about meetings or presentations are classified as Investor Presentation (IP) if they contain detailed presentation content, or Report Publication Announcement (RPA) if they announce report availability. However, this document is specifically about an investor meeting to explain half-year results, which aligns best with Investor Presentation (IP) category, as it is focused on investor communication about financial results and company performance, even though the actual report is to be released separately. Therefore, the correct classification is Investor Presentation (IP).
2024-08-28 Chinese
普莱柯关于使用闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the use of idle raised funds for cash management and the maturity redemption of such funds. It details the approval procedures, amounts involved, types of financial products, and the status of redemption. The document is relatively short (1773 characters) and focuses on the company's cash management activities related to raised funds, not a full financial report or audit. It is an update on capital usage and financing activities, specifically about the management of idle raised funds and their redemption. This fits the definition of a Capital/Financing Update (CAP).
2024-08-26 Chinese
普莱柯关于以集中竞价交易方式回购公司股份比例达1%的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the percentage of total shares, the price range, and the total amount spent. It references regulatory guidelines for share repurchases and provides updates on the implementation of the buyback plan. The document is not a full financial report, earnings release, or management discussion, but a specific update on share repurchase activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2024-08-19 Chinese
普莱柯关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, the total amount spent, and references the initial repurchase plan approval date and terms. The content focuses on the company's buyback activities and compliance with regulatory guidelines. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document fits the description of a 'Transaction in Own Shares' filing, which reports on the company's share repurchase activities.
2024-08-01 Chinese
普莱柯关于子公司获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company regarding its subsidiary obtaining a new veterinary drug registration certificate. It details the approval by the Ministry of Agriculture and Rural Affairs, the drug's basic information, development background, and the impact on the company. There are no financial statements, no mention of annual or quarterly reports, no voting results, no management changes, no earnings data, and no regulatory certifications. The document is a regulatory announcement about a new product approval, which fits best under general regulatory announcements that do not fit other categories. The document length is short (954 characters), and it is a standalone announcement, not a report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-07-31 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.